OraSure Technologies, Inc. (NASDAQ:OSUR) Shares Acquired by Marquette Asset Management LLC

Marquette Asset Management LLC raised its position in shares of OraSure Technologies, Inc. (NASDAQ:OSUR) by 44.4% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 69,345 shares of the medical instruments supplier’s stock after purchasing an additional 21,327 shares during the period. Marquette Asset Management LLC’s holdings in OraSure Technologies were worth $250,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Atom Investors LP bought a new stake in shares of OraSure Technologies during the third quarter valued at approximately $49,000. Creative Planning acquired a new stake in OraSure Technologies in the 3rd quarter valued at approximately $54,000. Mackenzie Financial Corp bought a new stake in OraSure Technologies during the 2nd quarter valued at $72,000. Intech Investment Management LLC acquired a new position in OraSure Technologies during the 3rd quarter worth $84,000. Finally, SkyView Investment Advisors LLC boosted its position in OraSure Technologies by 100.0% during the 2nd quarter. SkyView Investment Advisors LLC now owns 24,000 shares of the medical instruments supplier’s stock worth $102,000 after acquiring an additional 12,000 shares during the period. 93.50% of the stock is owned by institutional investors and hedge funds.

OraSure Technologies Trading Down 0.8 %

Shares of NASDAQ:OSUR opened at $3.67 on Wednesday. The company has a 50 day moving average of $3.84 and a 200-day moving average of $4.10. The firm has a market cap of $273.76 million, a P/E ratio of 24.47 and a beta of 0.05. OraSure Technologies, Inc. has a twelve month low of $3.52 and a twelve month high of $8.33.

OraSure Technologies (NASDAQ:OSUR) last released its earnings results on Wednesday, November 6th. The medical instruments supplier reported ($0.06) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.02. OraSure Technologies had a return on equity of 3.55% and a net margin of 5.07%. The firm had revenue of $39.92 million during the quarter, compared to the consensus estimate of $38.97 million. During the same period in the prior year, the firm posted $0.27 earnings per share. The firm’s revenue for the quarter was down 55.2% compared to the same quarter last year. Equities research analysts forecast that OraSure Technologies, Inc. will post -0.08 EPS for the current year.

Analysts Set New Price Targets

Separately, StockNews.com lowered OraSure Technologies from a “buy” rating to a “hold” rating in a report on Thursday, January 9th.

OraSure Technologies Profile

OraSure Technologies, Inc, together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company’s products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.